(Q40838811)

24 September 2017

title

The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma (English)

1 reference

24 September 2017

Aref I

1

1 reference

24 September 2017

Eapen L

series ordinal

2

1 reference

24 September 2017

Agboola O

series ordinal

3

1 reference

24 September 2017

Cross P

series ordinal

4

1 reference

24 September 2017

publication date

1 August 1998

1 reference

Radiotherapy and Oncology

24 September 2017

published in

1 reference

24 September 2017

volume

48

1 reference

24 September 2017

issue

2

1 reference

24 September 2017

page(s)

203-207

1 reference

Regression Models and Life-Tables (with discussion)

24 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Is Prostate Specific Antigen of Clinical Importance in Evaluating Outcome after Radical Prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate Specific Antigen after External Beam Radiotherapy for Prostatic Cancer: Followup

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

The value of serum prostate specific antigen determinations before and after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen--driven outcome analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Asymptotically Efficient Rank Invariant Test Procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate Specific Antigen in the Management of Patients with Localized Adenocarcinoma of the Prostate Treated with Primary Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

The effect of pelvic radiation therapy on serum levels of prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

Radical Prostatectomy and Radical Radiation Therapy for Clinical Stages T1 to 2 Adenocarcinoma of the Prostate: New Insights into Outcome from Repeat Biopsy and Prostate Specific Antigen Followup

1 reference

https://api.crossref.org/works/10.1016%2FS0167-8140%2898%2900061-9

7 January 2021

10.1016/S0167-8140(98)00061-9

Identifiers

DOI

1 reference

24 September 2017

1 reference